Fig. 5.

In vivo therapeutic efficacy of Dox-loaded liposomes in a KPC960 orthotopic model. A Quantification of CLDN4 expression in normal pancreas and pancreatic cancer tissues by Western blot analysis. B Immunohistochemical analysis of normal pancreas and pancreatic cancer tissue sections stained with an anti-CLDN4 antibody. C Treatment schedule. D Average weight of excised tumor tissues, including primary tumor and metastatic tumor, at 24 days. E Fluorescence images of major organs (liver(1), lung(2), spleen(3), kidney(4), and heart(5)) and tumor tissues (primary(6) and metastatic(7) tumors) from the orthotopic model at 24 days. F Colocalization of liposomes with DLCN4 in excised metastatic tumor tissue. G Apoptotic cell death at 15 days, assessed by TUNEL assay of tumor tissues, including primary tumor and metastatic tumor. H Mouse survival over the course of treatment (n = 8). (*P < 0.05, **P < 0.01)